High clinical inflammatory activity prior to the development of secondary progression: A prospective 5-year follow-up study

Multiple Sclerosis

Volumn 8, Issue 1, 2002, Pages 59-63

  Casanova i Estruch, B ^a   Coret, F ^a   Valero, C ^a   Landete, L ^a   Pascual, A ^a   Vilchez, J J ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Multiple sclerosis; Natural history of multiple sclerosis; Secondary progressive multiple sclerosis

Indexed keywords

BETA INTERFERON; PREDNISOLONE; STEROID;

ADULT; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROSPECTIVE STUDY;

ADULT; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0036185522     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458502ms773oa     Document Type: Article

References (11)

1. Defining the clinical course of multiple sclerosis: Results of an international survey
2. Course and prognosis of multiple sclerosis assessed by the computerised data processing of 349 patients
3. Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study
4. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
5. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
6. Interferon beta-1b in secondary progressive MS: Clinical and MRI results of a 3-year randomized controlled trial
7. SPECTRIMS study
8. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I: Clinical results of a multicenter, double-blind, randomized, placebo-controlled trial
9. a in relapsing MS
10. "Relapsing" vs "non-relapsing" SPMS: Different prognosis and responses to interferon therapy in the SPECTRIMS study
11. Relapses and progression of disability in multiple sclerosis